World Library  
Flag as Inappropriate
Email this Article

Esreboxetine

Article Id: WHEBN0026476724
Reproduction Date:

Title: Esreboxetine  
Author: World Heritage Encyclopedia
Language: English
Subject: Norepinephrine reuptake inhibitor
Collection:
Publisher: World Heritage Encyclopedia
Publication
Date:
 

Esreboxetine

Esreboxetine
Systematic (IUPAC) name
(2S)-2-[(S)-(2-ethoxyphenoxy)phenylmethyl]morpholine
Clinical data
Legal status
  • Uncontrolled
Routes Oral
Identifiers
CAS number  Y
ATC code None
PubChem
ChemSpider  N
UNII  Y
KEGG  Y
Chemical data
Formula C19H23NO3 
Mol. mass 313.391 g/mol
 N   

Esreboxetine is a selective norepinephrine reuptake inhibitor which was under development by Pfizer for the treatment of neuropathic pain and fibromyalgia but failed to show significant benefit over currently available medications and was discontinued.[1][2][3][4] It is the (+)-(S,S)-enantiomer of reboxetine and is even more selective in comparison.[1][5]

However, recently it has been shown that esreboxetine could be effective in fibromyalgia patients.[6]

See also

References

  1. ^ a b Matilda Bingham; Napier, Susan Jolliffe (2009). Transporters as Targets for Drugs (Topics in Medicinal Chemistry). Berlin: Springer. ISBN . 
  2. ^ Rao SG (October 2009). "Current progress in the pharmacological therapy of fibromyalgia". Expert Opinion on Investigational Drugs 18 (10): 1479–93. PMID 19732029. doi:10.1517/13543780903203771. 
  3. ^ "Search of: esreboxetine - List Results - ClinicalTrials.gov". 
  4. ^ "Musculoskeletal Report: Pfizer Stops Work on Esreboxetine for FM". 
  5. ^ Fish, P. V.; MacKenny, M.; Bish, G.; Buxton, T.; Cave, R.; Drouard, D.; Hoople, D.; Jessiman, A.; Miller, D.; Pasquinet, C.; Patel, B.; Reeves, K.; Ryckmans, T.; Skerten, M.; Wakenhut, F. (2009). "Enantioselective synthesis of (R)- and (S)-N-Boc-morpholine-2-carboxylic acids by enzyme-catalyzed kinetic resolution: application to the synthesis of reboxetine analogs". Tetrahedron Letters 50 (4): 389. doi:10.1016/j.tetlet.2008.11.025. 
  6. ^ Arnold, L. M., Hirsch, I., Sanders, P., Ellis, A. and Hughes, B. (2012), Safety and efficacy of esreboxetine in patients with fibromyalgia: A fourteen-week, randomized, double-blind, placebo-controlled, multicenter clinical trial. Arthritis & Rheumatism, 64: 2387–2397. doi: 10.1002/art.34390



This article was sourced from Creative Commons Attribution-ShareAlike License; additional terms may apply. World Heritage Encyclopedia content is assembled from numerous content providers, Open Access Publishing, and in compliance with The Fair Access to Science and Technology Research Act (FASTR), Wikimedia Foundation, Inc., Public Library of Science, The Encyclopedia of Life, Open Book Publishers (OBP), PubMed, U.S. National Library of Medicine, National Center for Biotechnology Information, U.S. National Library of Medicine, National Institutes of Health (NIH), U.S. Department of Health & Human Services, and USA.gov, which sources content from all federal, state, local, tribal, and territorial government publication portals (.gov, .mil, .edu). Funding for USA.gov and content contributors is made possible from the U.S. Congress, E-Government Act of 2002.
 
Crowd sourced content that is contributed to World Heritage Encyclopedia is peer reviewed and edited by our editorial staff to ensure quality scholarly research articles.
 
By using this site, you agree to the Terms of Use and Privacy Policy. World Heritage Encyclopedia™ is a registered trademark of the World Public Library Association, a non-profit organization.
 


Copyright © World Library Foundation. All rights reserved. eBooks from Project Gutenberg are sponsored by the World Library Foundation,
a 501c(4) Member's Support Non-Profit Organization, and is NOT affiliated with any governmental agency or department.